59576-27-1

Basic information

• Product Name: Ethanone, 1-(4-ethyl-2-pyridinyl)- (9CI)
• Synonyms: Ethanone, 1-(4-ethyl-2-pyridinyl)- (9CI)
• CAS NO: 59576-27-1
• Molecular Formula: C9H11NO
• Molecular Weight: 149.18974
• Product Categories: ACETYLGROUP
• Mol File: 59576-27-1.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ethanone, 1-(4-ethyl-2-pyridinyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-(4-ethyl-2-pyridinyl)- (9CI)(59576-27-1)
• EPA Substance Registry System: Ethanone, 1-(4-ethyl-2-pyridinyl)- (9CI)(59576-27-1)

Safety Data

• Hazardous Substances Data: 59576-27-1(Hazardous Substances Data)

Upstream product

• 92486-38-9 2-cyano-4-ethylpyridine 
• 917-64-6 methyl magnesium iodide 
• 127-19-5 N,N-dimethyl acetamide 
• 54453-91-7 2-bromo-4-ethylpyridine 
• 536-75-4 4-Ethylpyridine 
• 33252-32-3 4-ethylpyridin-2-amine 

Relevant articles and documents

Novel acid-type cyclooxygenase-2 inhibitors: Design, synthesis, and structure-activity relationship for anti-inflammatory drug

Cyclooxygenase (COX) is a key rate-limiting enzyme for prostaglandin (PG) production cascades in the human body. The mechanisms of both the anti-inflammation effects and the side-effects of traditional COX inhibitors are associated with the existence of two COX isoforms. Thus while COX-1 is predominantly expressed ubiquitously and constitutively, and it serves a housekeeping role in processes such as gastrointestinal (GI) mucosa protection, COX-2 is absent or exhibits a low level of expression in most tissues, and is highly upregulated in response to endotoxin, virus, inflammatory or tissue-injury stimuli/signals, and tumour promoter in the various types of organs, tissues, and cells. Furthermore, COX-2 contribution to PGE2 and PGI2 production evokes and sustains systemic or peripheral inflammatory disease, but it is not involved in the COX-1-mediated GI tract events. Also, hypersensitivity of aspirin owing to its inhibitory action against COX-1 is a significant concern clinically. Consequently, highly selective COX-2 inhibitors have been needed for the treatment of inflammatory- and inflammation related-diseases that include pyrexia, inflammation, pain, rheumatoid arthritis, osteoarthritis, and cancers. In this study, a series of novel [2-{[(4-substituted or 4,5-disubstituted)-pyridin-2-yl]carbonyl}-(5- or 6-substituted or 5,6-disubstituted)-1H-indol-3-yl]acetic acid analogues was designed, synthesized, and evaluated to identify potent and selective COX-2 inhibitors as potential agents against inflammatory diseases. As significant findings, the present study clarified unique structure-activity relationship of the analogues toward potent and selective COX-2 inhibition in vitro, and identified 2-{6-fluoro-2-[4-methyl-2-pridinyl)carbonyl]-1H-indol-3-yl}acetic acid as a potent and selective COX-2 inhibitor in vitro that demonstrated orally potent anti-inflammation efficacy against carrageenan-induced oedema formation in the foot of SPF/VAF male SD rats as a peripheral inflammation model in vivo.